Lars, please wake up and act against the corrupt behaviour of Mike Doustdar.
You spend your time on LinkedIn and other fora telling the world how wonderful Novo Nordisk is while one of your key lieutenants is allowed to get away with this behaviour. And what was once an “old IO issue” under Doustdar is now spreading to highly developed markets in Europe - just look below at what has happened in the UK with Novo about to get expelled from the Trade Association. This is what happens under a corrupt leader…
See below. This is a clear case of “Bribery” as mentioned in the detailed report if you care to read it….
“After Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national organization.
The Association of the British Pharmaceutical Industry (ABPI) regulates its 120-plus members through the Prescription Medicines Code of Practice Authority (PMCPA). Novo Nordisk was recently found (PDF) to be in violation of the U.K. national pharma code, and ABPI has an ongoing investigation into the company's conduct.
Now, Novo's U.K. general manager Pinder Sahota is resigning as ABPI president to avoid “becoming a distraction from the vital work of the ABPI,” the organization said in a statement.
For now, ABPI Vice President Susan Rienow, who is the country president for Pfizer, will fill in until the board decides on a new president.
Novo's Sahota was instated as the vice president of the ABPI in May 2021 and was bumped up to president in August of last year. He’s served as Novo’s U.K. general manager since May 2018.
Late last year, PMCPA reprimanded Novo Nordisk for multiple breaches of the national pharmaceutical code.
The crux of Novo’s wrongdoing centered on a LinkedIn post about an obesity webinar, which was sponsored by the company. However, the sponsorship was not clear on the post, according to the complainant who brought the case to the PMCPA. Since Novo’s Saxenda is a weight loss drug, the post “appeared to be promotional,” the complainant said.
PMCPA agreed, saying that it was “very concerned that Novo Nordisk did not recognize that this was a large-scale Saxenda promotional campaign, which Novo Nordisk knowingly paid for and which was disguised.”
You spend your time on LinkedIn and other fora telling the world how wonderful Novo Nordisk is while one of your key lieutenants is allowed to get away with this behaviour. And what was once an “old IO issue” under Doustdar is now spreading to highly developed markets in Europe - just look below at what has happened in the UK with Novo about to get expelled from the Trade Association. This is what happens under a corrupt leader…
See below. This is a clear case of “Bribery” as mentioned in the detailed report if you care to read it….
“After Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national organization.
The Association of the British Pharmaceutical Industry (ABPI) regulates its 120-plus members through the Prescription Medicines Code of Practice Authority (PMCPA). Novo Nordisk was recently found (PDF) to be in violation of the U.K. national pharma code, and ABPI has an ongoing investigation into the company's conduct.
Now, Novo's U.K. general manager Pinder Sahota is resigning as ABPI president to avoid “becoming a distraction from the vital work of the ABPI,” the organization said in a statement.
For now, ABPI Vice President Susan Rienow, who is the country president for Pfizer, will fill in until the board decides on a new president.
Novo's Sahota was instated as the vice president of the ABPI in May 2021 and was bumped up to president in August of last year. He’s served as Novo’s U.K. general manager since May 2018.
Late last year, PMCPA reprimanded Novo Nordisk for multiple breaches of the national pharmaceutical code.
The crux of Novo’s wrongdoing centered on a LinkedIn post about an obesity webinar, which was sponsored by the company. However, the sponsorship was not clear on the post, according to the complainant who brought the case to the PMCPA. Since Novo’s Saxenda is a weight loss drug, the post “appeared to be promotional,” the complainant said.
PMCPA agreed, saying that it was “very concerned that Novo Nordisk did not recognize that this was a large-scale Saxenda promotional campaign, which Novo Nordisk knowingly paid for and which was disguised.”